Vancomycin: Difference between revisions
(→Common) |
(Strip excess bold) |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[ | *Type: [[Is DrugClass::Glycopeptide]] | ||
*Dosage Forms: | *Dosage Forms: | ||
**IV | **IV | ||
**PO: Mix IV form with 30mL water | **PO: Mix IV form with 30mL water | ||
**PR: Mix IV form with 100mL NS | **PR: Mix IV form with 100mL NS | ||
*Common Trade Names: Vancocin | *Common Trade Names: Vancocin | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Loading Doses=== | ===Loading Doses=== | ||
*15-20mg/kg IV loading dose<ref>Ryback M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66(1):82-98. </ref> | *15-20mg/kg IV loading dose<ref>Ryback M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66(1):82-98. </ref> | ||
*Sample Loading Dose Table (individual ED guidelines may differ) | *Sample Loading Dose Table (individual ED guidelines may differ) | ||
** | **<40kg: 750mg IV | ||
** | **40-59kg: 1000mg IV | ||
** | **60-90kg: 1500mg IV | ||
** | **>90kg: 2000mg IV | ||
*Alternative loading dose for serious infections: 20-25mg/kg IV | *Alternative loading dose for serious infections: 20-25mg/kg IV | ||
*Loading doses of 30mg/kg has shown improved target trough levels at 12 hrs with no difference in nephrotoxicity<ref>Rosini JM, et al. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother. 2015; 49(1):6-13.</ref><ref>Rosini JM, et al. High single-dose vancomycin loading is not associated with increased nephrotoxicity in emergency department sepsis patients. Acad Emerg Med. 2016 Feb 6.</ref> | *Loading doses of 30mg/kg has shown improved target trough levels at 12 hrs with no difference in nephrotoxicity<ref>Rosini JM, et al. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother. 2015; 49(1):6-13.</ref><ref>Rosini JM, et al. High single-dose vancomycin loading is not associated with increased nephrotoxicity in emergency department sepsis patients. Acad Emerg Med. 2016 Feb 6.</ref> | ||
| Line 21: | Line 20: | ||
===Maintenance=== | ===Maintenance=== | ||
All: Adjust repeat doses based on serum levels | |||
* | *<50kg: 500mg IV q12h | ||
* | *50-69kg: 750mg IV q12h | ||
* | *>70kg: 1000mg IV q12h | ||
*Alternative (All Weights): 10-15mg/kg IV q12 | *Alternative (All Weights): 10-15mg/kg IV q12 | ||
*Adjust dose based on serum levels | *Adjust dose based on serum levels | ||
=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Vancomycin]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
All: Adjust repeat doses based on serum levels | |||
===General (<7 Days Old)=== | ===General (<7 Days Old)=== | ||
* | *<1.2kg | ||
**15mg/kg IV q24h | **15mg/kg IV q24h | ||
**First Dose: 15mg/kg IV x 1 | **First Dose: 15mg/kg IV x 1 | ||
* | *1.2-2kg | ||
**10-15mg/kg IV q12-18h | **10-15mg/kg IV q12-18h | ||
**First Dose: 10-15mg/kg IV x 1 | **First Dose: 10-15mg/kg IV x 1 | ||
* | *>2.1kg | ||
**10-15mg/kg IV q8-12h | **10-15mg/kg IV q8-12h | ||
**First Dose: 10-15mg/kg IV x 1 | **First Dose: 10-15mg/kg IV x 1 | ||
===General (7 Days - 1 Month Old)=== | ===General (7 Days - 1 Month Old)=== | ||
* | *<1.2kg | ||
**15mg/kg IV q24h | **15mg/kg IV q24h | ||
**First Dose: 15mg/kg IV x 1 | **First Dose: 15mg/kg IV x 1 | ||
* | *1.2-2kg | ||
**10-15mg/kg IV q8-12h | **10-15mg/kg IV q8-12h | ||
**First Dose: 10-15mg/kg IV x 1 | **First Dose: 10-15mg/kg IV x 1 | ||
* | *>2.1kg | ||
**15-20mg/kg IV q8 | **15-20mg/kg IV q8 | ||
**First Dose: 15-20mg/kg IV x 1 | **First Dose: 15-20mg/kg IV x 1 | ||
| Line 82: | Line 76: | ||
*Info: Repeat dosing may require up to 1200-1500mg IV q12h or 10mg/kg IV q8 | *Info: Repeat dosing may require up to 1200-1500mg IV q12h or 10mg/kg IV q8 | ||
=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Vancomycin]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
| Line 187: | Line 178: | ||
| ||[[MSSA]]||'''S''' | | ||[[MSSA]]||'''S''' | ||
|- | |- | ||
| ||[[MRSA]]||'''S''' | | ||[[MRSA]]||'''[[Has MRSA::S]]''' | ||
|- | |- | ||
| ||[[CA-MRSA]]||'''S''' | | ||[[CA-MRSA]]||'''S''' | ||
Latest revision as of 09:15, 22 March 2026
General
- Type: Glycopeptide
- Dosage Forms:
- IV
- PO: Mix IV form with 30mL water
- PR: Mix IV form with 100mL NS
- Common Trade Names: Vancocin
Adult Dosing
Loading Doses
- 15-20mg/kg IV loading dose[1]
- Sample Loading Dose Table (individual ED guidelines may differ)
- <40kg: 750mg IV
- 40-59kg: 1000mg IV
- 60-90kg: 1500mg IV
- >90kg: 2000mg IV
- Alternative loading dose for serious infections: 20-25mg/kg IV
- Loading doses of 30mg/kg has shown improved target trough levels at 12 hrs with no difference in nephrotoxicity[2][3]
- Adjust maintenance dose based on serum levels
Maintenance
All: Adjust repeat doses based on serum levels
- <50kg: 500mg IV q12h
- 50-69kg: 750mg IV q12h
- >70kg: 1000mg IV q12h
- Alternative (All Weights): 10-15mg/kg IV q12
- Adjust dose based on serum levels
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Ascending cholangitis | 15-20mg/kg | MRSA coverage for severe sepsis |
| Brain abscess | 15mg/kg IV q12hr | Trauma/Post-surgical |
| Cellulitis | 20mg/kg IV q12hrs | Inpatient |
| Clostridium difficile | 125 mg PO four times daily for 10 days | Severe |
| Clostridium difficile | 125 mg PO four times daily for 10 days | Non-Severe |
| Diabetic foot infection | 15-20mg/kg IV q12hrs | Inpatient DFI |
| Discitis | 15-20 mg/kg IV BID | Inpatient Therapy |
| Endocarditis | 30mg/kg/day IV in 2 doses | MRSA Native Valve Endocarditis |
| Endocarditis | 30mg/kg/day IV in 2 doses | Prosthetic Valve Endocarditis (Early) |
| Endocarditis | 15-20 mg/kg IV BID daily | IVDA Endocarditis |
| Epidural abscess (spinal) | 15-20mg/kg BID | Empiric |
| Infectious tenosynovitis | 25-30 mg/kg IV loading dose then 15-20mg/kg IV q12hrs | Empiric |
| Ludwig's angina | 15-20 mg/kg IV q8 hrs (max 2 g per dose) | Immunocompromised, MRSA |
| Mastoiditis | 15-20mg/kg IV q12 hours | Empiric |
| Open fracture | 1 g IV (immediately and q12 hours x 2 total doses) | Grade III Fractures |
| Orbital cellulitis | 15-20mg/kg IV BID | Inpatient |
| Osteomyelitis | 1g IV q12h | Postoperative |
| Osteomyelitis | 1g IV q12h | IVDU |
| Osteomyelitis | 1g IV q12h | DM/Vascular insufficiency |
| Osteomyelitis | 1g IV q12h | Elderly/Hematogenous |
| Peritoneal dialysis-associated peritonitis | 30mg/kg loading followed by 0.6 mg/kg IP daily | Empiric IP |
| Pneumonia (main) | 15–20 mg/kg IV q8-12h (target AUC/MIC 400-600) | ICU, Risk of MRSA |
| Pneumonia (main) | 15-20 mg/kg IV q8-12h | VAP, High Risk |
| Pneumonia (main) | 15-20 mg/kg IV q8-12h | HAP, High Risk |
| Septic bursitis | 25-30 mg/kg IV loading then 15-20 mg/kg IV | Inpatient |
| Staphylococcal enterocolitis | 125-500mg PO q6h | Staphylococcal enterocolitis |
| Suppurative parotitis | 15-20mg/kg IV BID daily | Inpatient |
Pediatric Dosing
All: Adjust repeat doses based on serum levels
General (<7 Days Old)
- <1.2kg
- 15mg/kg IV q24h
- First Dose: 15mg/kg IV x 1
- 1.2-2kg
- 10-15mg/kg IV q12-18h
- First Dose: 10-15mg/kg IV x 1
- >2.1kg
- 10-15mg/kg IV q8-12h
- First Dose: 10-15mg/kg IV x 1
General (7 Days - 1 Month Old)
- <1.2kg
- 15mg/kg IV q24h
- First Dose: 15mg/kg IV x 1
- 1.2-2kg
- 10-15mg/kg IV q8-12h
- First Dose: 10-15mg/kg IV x 1
- >2.1kg
- 15-20mg/kg IV q8
- First Dose: 15-20mg/kg IV x 1
General (1 Month - 11 Years)
- 10-15mg/kg IV q6-8h
- First Dose: 10-15mg/kg IV x 1
- Max: 1 gram per dose
General (12 - 16 Years)
- 1000mg IV q12h
- First Dose: 1000mg IV x 1
- Alt: 10-15mg/kg IV q12
- Info: Repeat dosing may require up to 1200-1500mg IV q12h or 10mg/kg IV q8
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Brain abscess | 15mg/kg IV q6hrs | Pediatric Trauma/Post-surgical |
| Cellulitis | 15mg/kg IV q6hrs | Pediatric Inpatient |
| Clostridium difficile | 10mg/kg PO QID x 10 days (max 125mg/dose) | Pediatric Non-Severe |
| Endocarditis | 15mg/kg IV q6hrs (max 2g/dose) | Pediatric Empiric |
| Epidural abscess (spinal) | 15mg/kg IV q6hrs | Pediatric Empiric |
| Ludwig's angina | 15mg/kg IV q6hrs | Pediatric MRSA |
| Mastoiditis | 15mg/kg IV q6hrs | Pediatric MRSA |
| Neutropenic fever | 15mg/kg IV q6hrs | Pediatric, MRSA/catheter |
| Open fracture | 15mg/kg IV (max 1g) then q12hrs x 2 doses | Pediatric Grade III |
| Orbital cellulitis | 15mg/kg IV q6hrs | Pediatric Inpatient |
| Osteomyelitis | 15mg/kg IV four times daily | Sickle Cell Disease |
| Osteomyelitis | 10mg/kg q6 h | Children |
| Osteomyelitis | 15mg/kg load, then reduce dose | Newborn |
| Pediatric fever of uncertain source | 15mg/kg | 90 days to 36 months consider adding |
| Pneumonia (peds) | 15mg/kg/dose q6hrs IV | Hospitalized PICU severely ill |
| Staphylococcal enterocolitis | 40mg/kg/day PO divided q6h (max 2g/day) | Staphylococcal enterocolitis |
| Suppurative parotitis | 15mg/kg IV q6hrs | Pediatric Inpatient |
| Ventriculoperitoneal shunt infection | age-based dosing | Empiric with Cefotaxime or Ceftriaxone |
Special Populations
- Drug ratings in pregnancy: C
- Lactation: Probably safe
- Renal Dosing
- Adult
- CrCl 50-90: 15mg/kg x1, then usual dose q12-24h
- CrCl 10-50: 15mg/kg x1, then usual dose q24h-96h
- CrCl <10: 15mg/kg x1, then usual dose q4-7 days
- Hemodialysis: Give supplement only if high-flux dialyzer used
- Peritoneal dialysis: No supplement
- Pediatric
- CrCl 10-50: give q18-48h
- CrCl <10: give q48-96h
- Hemodialysis: Give supplement only if high-flux dialyzer used
- Peritoneal dialysis: No supplement
- Adult
- Hepatic Dosing (Adult & Pediatric)
- Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis
- Severe hypotension (rapid IV use) - not much evidence but consider anti-histamine[4]:
- 1.25-1.67mg/kg/dose diphenhydramine IV to pediatric patients
- 25 - 50mg diphenhydramine IV to adults
- Thrombophlebitis
- Tissue necrosis (if extravasation)
- vasculitis
- Exfoliative dermatitis
- Stevens-Johnson Syndrome
- Toxic Epidermal Necrolysis
- Drug rash with eosinophilia and systemic symptoms
- Interstitial nephritis
- Nephrotoxicity
- Ototoxicity
- Neutropenia
- Thrombocytopenia
- Superinfection
- Clostridium difficile
Common
- Vancomycin infusion reaction (rapid IV use) - formerly "red man syndrome"[5]
- Hypotension(rapid IV use)
- Fever
- Nausea
- Rigors
- Eosinophilia
- Rash
- Urticaria
- Phlebitis
- Tinnitus
- Dizziness/Vertigo
- Elevated BUN/Creatinine
- Vomiting (PO use)
- Flatulence (PO use)
Pharmacology
- Half-life: 4-6h (7.5 days ESRD)
- Metabolism: CYP450
- Excretion:
- IV route: Urine
- PO Route: Minimal systemic absorption unless intestinal inflammation or renal impairment
- Mechanism of Action
- Bactericidal against S. aureus and pneumococci
- Bacteriostatic against enterococci[6]
Antibiotic Sensitivities[7]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Ryback M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66(1):82-98.
- ↑ Rosini JM, et al. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother. 2015; 49(1):6-13.
- ↑ Rosini JM, et al. High single-dose vancomycin loading is not associated with increased nephrotoxicity in emergency department sepsis patients. Acad Emerg Med. 2016 Feb 6.
- ↑ Lyon GD and Bruce DL. Diphenhydramine reversal of vancomycin-induced hypotension. Anesth Analg. 1988 Nov;67(11):1109-10.
- ↑ Alvarez-Arango, S, Ogunwole, SM, Sequist, TD, Burk, CM, Blumenthal, KG. Vancomycin infusion reaction—moving beyond “red man syndrome.” N Engl J Med. 2021;384:1283-1286. doi:10.1056/NEJMp2031891
- ↑ Bactericidal agents in the treatment of MRSA infections—the potential role of daptomycin. J. Antimicrob. Chemother. (2006) 58 (6): 1107-1117.
- ↑ Sanford Guide to Antimicrobial Therapy 2014
